The data source for this dataset is the NI Vaccine Management System (VMS). VMS holds vaccination reports for COVID-19 and influenza vaccines which were either administered in NI or to NI residents. This dataset is an aggregated summary of COVID-19 vaccinations recorded in VMS. It is effectively a day-by-day count of living people vaccinated by dose, age band (on the day that the dataset was extracted from VMS) and LGD of residence. Aggregated summary data from VMS is published daily to the NI COVID-19 Vaccinations Dashboard. This dataset is updated weekly and allows NI vaccination coverage to be included in the GOV.UK Coronavirus (COVID-19) in the UK dashboard.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

The initial virulence and invasiveness of a bacterial strain may play an important role in leading to a maximally efficacious attenuated live vaccine. Here we show that χ9909, derived from Salmonella Typhimurium UK-1 χ3761 (the most virulent S. Typhimurium strain known to us), is effective in protecting mice against lethal UK-1 and 14028S (less virulent S. Typhimurium strain) challenge. As opposed to this, 14028S-derived vaccine χ12359 induces suboptimal levels of protection, with survival percentages that are significantly lower when challenged with lethal UK-1 challenge doses. T-cell assays have revealed that significantly greater levels of Th1 cytokines IFN-γ and TNF-α were secreted by stimulated T-lymphocytes obtained from UK-1(ΔaroA) immunized mice than those from mice immunized with 14028S(ΔaroA). In addition, UK-1(ΔaroA) showed markedly higher colonizing ability in the spleen, liver, and cecum when compared to 14028S(ΔaroA). Enumeration of bacteria in fecal pellets has also revealed that UK-1(ΔaroA) can persist in the host for over 10 days whereas 14028S(ΔaroA) titers dropped significantly by day 10. Moreover, co-infection of parent strains UK-1 and 14028S resulted in considerably greater recovery of the former in multiple mucosal and gut associated lymphatic tissues. Mice immunized with UK-1(ΔaroA) were also able to clear UK-1 infection remarkably more efficiently from the target organs than 14028S(ΔaroA). Together, these results provide ample evidence to support the hypothesis that attenuated derivatives of parent strains with higher initial virulence make better vaccines.

Data related to the Table and figures in the publication (in title)

Table 1 shows Particle size measured by dynamic light scattering (mean±SD), n= 12

Figure 5 shows the Change in particle size (measured by dynamic light scattering) upon exposure to 0.1M HCl, which is simulating the acidic environment in a fasted tilapia stomach. Means are shown. Error bars reflect the SD. N=12

Fig 6 shows the pH measured in the different sections of the gastro- intestinal tract of fasted and fed tilapia (mean ± SD), N=5

Fig. 7 Shows the Cumulative percentage mortality in the 3 groups following oral gavage with: (ai) PBS in the negative control group; (aii) Blank Eudragit microparticles; (b) GBS-loaded Eudragit microparticles, and challenge by immersion using a homologous strain of Streptococus agalatiae sequence type on day 21 post-gavage. Error bars represent SD from 4 replicate tanks (25 fish per tank) for each of 3 treatment groups.

The data are shown in Excel files. Data was collected using dynamic light scattering (Table 1, Figure 5), by measuring pH using a probe (Figure 6), and by counting the numbers of fish which survived the pathogen challenge with time.

Infoveillance, wastewater and national data.R - The R script used for the analyses and figures present in the manuscript. SWalesNormqPCRandGT.csv - File containing the data used for this manuscript, including the following columns: Study Week: The number of weeks into the period used for this study. WC Date: The date of the first day of each week used for this study. COVIDCount: The average normalised copy numbers of SARS-CoV-2 across sites and dates in South Wales for each week. covid symptoms: The relative prevalence of Google searches for the string “covid symptoms’. covid test: The relative prevalence of Google searches for the string “covid test’. covid vaccine: The relative prevalence of Google searches for the string “covid vaccine’. covid rules: The relative prevalence of Google searches for the string “covid rules’. covid lockdown: The relative prevalence of Google searches for the string “covid lockdown’. Cases: The number of COVID cases reported by Welsh Government for that week. Deaths: The number of COVID-related deaths reported by Welsh Government for that week. Vaccines: The number of COVID vaccines reported by Welsh Government for that week.

Summary of stool shedding by participants between Day 0 (including pre-challenge) until completion of challenge, according to vaccine group allocation, challenge outcome and phase of shedding.

Participant characteristics by enrolled vaccine group.